Mesoblast Limited (OTCMKTS:MEOBF – Get Free Report) shares crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.63 and traded as high as $1.70. Mesoblast shares last traded at $1.70, with a volume of 1,000 shares.
Mesoblast Stock Up 9.7%
The company’s 50 day moving average price is $1.62 and its 200-day moving average price is $1.63.
About Mesoblast
Mesoblast Limited (OTCMKTS:MEOBF) is a global leader in regenerative medicine focused on the development and commercialization of innovative allogeneic cell therapies. The company’s proprietary platform harnesses mesenchymal lineage adult stem cells to address a range of inflammatory and immunological conditions. Mesoblast’s pipeline includes multiple late-stage and marketed products that target serious diseases with high unmet medical needs.
The company’s lead product, remestemcel-L (Ryvicor/Ryoncil), is under development for the treatment of steroid-refractory acute graft versus host disease in pediatric patients and has received conditional approval for certain indications in Japan.
See Also
- Five stocks we like better than Mesoblast
- Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
- CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks
- Why ASML’s AI Monopoly Is Still Getting Stronger
- Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings
